Skip to main
SKIN
SKIN logo

SKIN Stock Forecast & Price Target

SKIN Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 0%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

Beauty Health's strong 4Q23 performance, reporting revenue of $96.8 million, exceeded both prior internal estimates and street expectations, suggesting robust demand for its product offerings. The company achieved a significant increase in average selling price (ASP) for total systems, rising approximately 20% quarter-over-quarter to $28.8K, which reflects a favorable channel mix with an increased percentage of direct sales. Additionally, the growth in consumables contributed positively to revenue, indicating a promising trajectory for Beauty Health's overall financial performance despite the back-end weighted EBITDA guidance.

Bears say

Beauty Health's stock outlook is negatively impacted by a significant decline in new placements of core delivery systems, which fell over 30% year-over-year and quarter-over-quarter, falling short of earlier projections. This deceleration in growth raises concerns regarding future consumable sales, which are essential for achieving management's profitability targets in 2024. Furthermore, management's revenue and adjusted EBITDA guidance for the first quarter of 2024 indicates a solid miss compared to prior estimates, suggesting potential difficulties in meeting full-year performance goals.

SKIN has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 0% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of The Beauty Health Company and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About The Beauty Health Company (SKIN) Forecast

Analysts have given SKIN a Buy based on their latest research and market trends.

According to 3 analysts, SKIN has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

The Beauty Health Company (SKIN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.